程序性细胞死亡在卵巢癌铂耐药中的作用

徐娟 ,  周晅 ,  罗晨辉

中南大学学报(医学版) ›› 2026, Vol. 51 ›› Issue (5) : 1057 -1069.

PDF (658KB)
中南大学学报(医学版) ›› 2026, Vol. 51 ›› Issue (5) : 1057 -1069. DOI: 10.11817/j.issn.1672-7347.2026.260080
综述

程序性细胞死亡在卵巢癌铂耐药中的作用

作者信息 +

Role of programmed cell death in platinum resistance in ovarian cancer

Author information +
文章历史 +
PDF (672K)

摘要

卵巢癌是全球女性生殖系统中病死率最高的恶性肿瘤,化疗耐药特别是铂耐药是限制其预后改善的主要因素,相关机制涉及癌细胞对多种程序性细胞死亡途径的复杂调控与逃逸。双硫死亡由溶质载体家族7成员11(solute carrier family 7 member 11,SLC7A11)高表达在葡萄糖饥饿条件下触发,与铁死亡共享上游调控节点;钠死亡由瞬时受体电位阳离子通道亚家族M成员4(transient receptor potential cation channel subfamily M member 4,TRPM4)介导的Na⁺过载驱动,其作用尚待深入研究。其他程序性细胞死亡途径通过肿瘤蛋白p53、caspase家族、半胱氨酸天冬氨酸特异性蛋白酶、谷胱甘肽等关键调控分子交织成动态调控网络:自噬可抑制焦亡;铁死亡与焦亡可通过活性氧/NOD样受体热蛋白结构域相关蛋白3轴协同放大细胞杀伤效应。铁死亡与铜死亡共享谷胱甘肽代谢轴,铁死亡与双硫死亡的交互作用可在特定代谢压力下由拮抗向协同转换;铁死亡与钠死亡通过腺苷三磷酸耗竭、活性氧累积、线粒体损伤的级联反应相互促进;泛凋亡则可通过多死亡通路的同步激活,克服癌细胞对单一死亡模式的抵抗。系统综述双硫死亡、钠死亡、凋亡、自噬、坏死性凋亡、焦亡、铁死亡、铜死亡及泛凋亡等多种程序性死亡模式在卵巢癌铂耐药中的作用及其交互网络,有望为逆转铂耐药、优化临床治疗策略提供坚实的理论基础和潜在的转化方向。

Abstract

Ovarian cancer is the most lethal malignancy of the female reproductive system worldwide. Chemoresistance, particularly platinum resistance, is a major factor limiting improvement in prognosis, and its underlying mechanisms involve complex regulation of and escape from multiple programmed cell death pathways in cancer cells. Disulfidptosis is triggered by high expression of solute carrier family 7 member 11 (SLC7A11) under glucose starvation and shares upstream regulatory nodes with ferroptosis. Necrosis by sodium overload is driven by sodium ion overload mediated by transient receptor potential cation channel subfamily M member 4 (TRPM4), but its role remains to be further investigated. Other programmed cell death pathways are interwoven into a dynamic regulatory network through key regulatory molecules such as tumor protein p53, the caspase family, cysteine-aspartic proteases, and glutathione. Autophagy can inhibit pyroptosis; ferroptosis and pyroptosis can synergistically amplify cell-killing effects through the reactive oxygen species/NOD-like receptor thermal protein domain-associated protein 3 axis; ferroptosis and cuproptosis share the glutathione metabolic axis; and the interaction between ferroptosis and disulfidptosis can shift from antagonism to synergy under specific metabolic stress. Ferroptosis and necrosis by sodium overload mutually promote each other through cascades involving adenosine triphosphate depletion, reactive oxygen species accumulation, and mitochondrial damage. PANoptosis can overcome cancer-cell resistance to a single mode of cell death through the simultaneous activation of multiple cell death pathways. A comprehensive review of the roles and interactive networks of various programmed cell death modalities, including disulfidptosis, necrosis by sodium overload, apoptosis, autophagy, necroptosis, pyroptosis, ferroptosis, cuproptosis, and PANoptosis, in platinum resistance in ovarian cancer is expected to provide a solid theoretical basis and potential translational directions for reversing platinum resistance and optimizing clinical treatment strategies.

关键词

卵巢癌 / 铂耐药 / 双硫死亡 / 钠死亡 / 程序性细胞死亡 / 妇科肿瘤

Key words

ovarian cancer / platinum resistance / disulfidptosis / necrosis by sodium overload / programmed cell death / gynecologic tumors

引用本文

引用格式 ▾
徐娟,周晅,罗晨辉. 程序性细胞死亡在卵巢癌铂耐药中的作用[J]. 中南大学学报(医学版), 2026, 51(5): 1057-1069 DOI:10.11817/j.issn.1672-7347.2026.260080

登录浏览全文

4963

注册一个新账户 忘记密码

卵巢癌(ovarian cancer,OC)是病死率最高的妇科恶性肿瘤,对全球女性健康构成重大威胁[1]。尽管手术联合铂类药物化疗对部分患者产生了比较好的疗效,但超过70%的患者会出现铂耐药[2],导致5年生存率不足30%[3]。因此,研究并解决铂耐药问题是改善卵巢癌患者预后的关键。
铂类药物主要通过诱导DNA损伤、产生活性氧及破坏线粒体功能来激活癌细胞死亡程序[4];然而,癌细胞能够通过多种途径削弱对这些死亡信号的应答,从而获得耐药表型。近年来,程序性细胞死亡(programmed cell death,PCD)的概念不断扩展,从经典的凋亡逐步延伸至自噬(autophagy)、坏死性凋亡(necroptosis)、焦亡(pyroptosis)、铁死亡(ferroptosis)、铜死亡(cuproptosis)、泛凋亡(panoptosis),乃至近期提出的双硫死亡(disulfidptosis)和钠死亡(necrosis by sodium overload,NECSO)等多种形式。凋亡是经典的胱天蛋白酶(caspase)依赖性死亡,分为内源性的线粒体途径[由B淋巴细胞瘤-2(B-cell lymphoma-2,Bcl-2)家族蛋白调控线粒体内细胞色素c的释放]和外源性的死亡受体途径,其生理意义在于清除受损或多余细胞而不引发炎症[5]。在肿瘤中,凋亡逃逸是耐药的基础。自噬是一种溶酶体介导的降解过程,通过形成自噬体包裹受损的细胞器或蛋白质聚集体,维持代谢稳态和细胞生存,但在特定条件下也可促进细胞死亡;其双向调控作用在化疗抵抗中尤为突出[6]。坏死性凋亡由受体相互作用蛋白激酶1(receptor-interacting protein kinase,RIPK)1/RIPK3/混合谱系激酶结构域样蛋白(mixed lineage kinase domain-like protein,MLKL)级联信号驱动,导致膜破裂和内容物释放,兼具坏死形态与程序性调控,可作为凋亡受阻时的备用死亡途径[7]。焦亡则由焦孔素(gasdermin,GSDM)家族的GSDMD、GSDME介导,二者可被炎症小体下游激活的caspase-1或化疗诱导的caspase-3切割,在细胞膜上形成膜孔,从而导致白细胞介素1β(interleukin-1 beta,IL-1β)等促炎性细胞因子的释放,属于炎性死亡,在抗肿瘤免疫与耐药微环境中发挥双刃剑的作用[8]。铁死亡是一种铁依赖性的脂质过氧化驱动死亡,核心轴为胱氨酸/谷氨酸反向转运体(cystine/glutamate antiporter,System Xc⁻)-谷胱甘肽(glutathione,GSH)-谷胱甘肽过氧化物酶4(glutathione peroxidase 4,GPX4),当GPX4失活或胱氨酸摄取受阻时,脂质过氧化物堆积导致膜破裂[9];其与代谢重编程、免疫调节密切相关,已成为抑制耐药的研究热点。铜死亡是新定义的铜依赖性死亡,其调控机制不同于铁死亡、凋亡等经典死亡通路:胞内铜离子经铁氧还蛋白1(ferredoxin 1,FDX1)还原后与线粒体中的脂酰化蛋白直接结合,引发蛋白质毒性应激介导细胞死亡;铜转运体铜转运蛋白1(copper transport protein 1,CTR1)、铜离子转运ATP酶α/β肽(ATPase copper transporting alpha/beta,ATP7A/B)同时介导铂类药物摄取与外排,连接铜稳态与铂耐药[10]。
值得关注的是,双硫死亡与钠死亡是近期提出的2种非经典程序性细胞死亡方式,其在卵巢癌铂耐药中的潜在价值尚未被充分挖掘。其中,双硫死亡由溶质载体家族7成员11(solute carrier family 7 member 11,SLC7A11)高表达介导,在葡萄糖饥饿条件下触发,核心特征为胞内还原型烟酰胺腺嘌呤二核苷酸磷酸(reduced nicotinamide adenine dinucleotide phosphate,NADPH)耗竭与二硫化物应激导致细胞骨架崩解[11],是目前唯一以肌动蛋白细胞骨架的二硫键应激为直接执行步骤的死亡方式,这使其在肿瘤治疗中具有独特的干预潜力。钠死亡则由瞬时受体电位阳离子通道亚家族M成员4(transient receptor potential cation channel subfamily M member 4,TRPM4)持续激活介导的Na⁺过载驱动,引发膜去极化和渗透性坏死[12],是一种以离子稳态失衡为核心驱动的新型调节性坏死,其特殊性在于将离子毒性与线粒体代谢直接关联。
上述细胞死亡模式在卵巢癌铂耐药中并非孤立发挥作用,而是通过共享分子执行因子、代谢通路和炎症信号轴,构建出高度动态且具有代偿能力的死亡调控网络[13]。正是这种多通路间的相互协同与代偿,使得癌细胞在面对铂类药物压力时能够灵活切换死亡模式,最终形成耐药。因此,厘清不同死亡通路间的交互调控机制,对于开发联合靶向策略、打破癌细胞的耐药平衡具有重要意义。本文梳理了双硫死亡、钠死亡、凋亡、自噬、坏死性凋亡、焦亡、铁死亡、铜死亡和泛凋亡在卵巢癌铂耐药中的研究进展,聚焦其独特机制与交互网络,并在此基础上提出多通路协同干预的治疗新视角,为克服铂耐药、优化临床策略提供理论依据与转化思路。

1 程序性细胞死亡在卵巢癌铂耐药中的作用

1.1 双硫死亡

双硫死亡是一种新型程序性细胞死亡方式,由癌细胞在葡萄糖饥饿时高表达SLC7A11引发,导致NADPH耗竭、氧化还原系统崩溃和二硫化物积累,最终引起细胞骨架蛋白质变性[14]。其机制还涉及SLC7A11、溶质载体家族7成员2(solute carrier family 7 member 2,SLC7A2)、核糖体蛋白1(ribophorin I,RPN1)和Nck相关蛋白1(Nck-associated protein 1,NCKAP1)等关键基因,提示双硫死亡的下游效应可能不局限于细胞骨架损伤[15]。在卵巢癌中,双硫死亡途径与免疫细胞浸润和肿瘤微环境密切相关[16],其中SLC7A11可作为潜在治疗靶点,提升耐药卵巢癌细胞对铂类化疗的敏感性,有望逆转铂耐药,为未来的卵巢癌研究和临床应用提供新思路[17]。

1.2 钠死亡

钠死亡是一种由Na⁺过载触发的程序性坏死,核心触发机制为TRPM4的持续激活导致Na⁺大量内流,引发细胞膜去极化、渗透失衡和坏死,是一种独特的细胞死亡途径[12]。一项泛癌数据库分析[18]结果显示,TRPM4在多种肿瘤(包括卵巢癌)中表达上调,并与患者不良预后及免疫微环境改变相关。已有研究[19]证实,TRPM4在耐药癌细胞中表达上调,抑制TRPM4可恢复耐药细胞对药物的敏感性,过表达TRPM4则会增强细胞耐药性。这一研究显示TRPM4介导的Na⁺调控可能参与化疗耐药机制,为TRPM4作为化疗耐药调控因子提供了功能证据。此外,在其他肿瘤模型中,TRPM4被报道与细胞增殖、迁移及化疗反应相关[20],提示其可能通过调控离子稳态和应激信号间接影响耐药表型。未来可围绕TRPM4-Na⁺稳态/代谢重塑,结合顺铂处理模型与基因干预实验,验证其在铂耐药形成与逆转中的功能潜力。

与凋亡、自噬等传统死亡方式相比,双硫死亡和钠死亡在卵巢癌铂耐药中可能具有特殊价值。铂耐药细胞常高表达SLC7A11并发生谷胱甘肽代谢重编程,这不仅增强了细胞抗氧化能力,也使细胞对双硫死亡更为敏感:在葡萄糖剥夺或NADPH合成受抑时,高表达SLC7A11的耐药细胞会优先进入双硫死亡,而敏感细胞相对耐受[21]。同时,铂耐药常伴有Bcl-2家族蛋白上调及caspase失活导致的凋亡逃逸[22],而双硫死亡作为一种独立于经典凋亡通路的新型细胞死亡方式,可能为清除凋亡耐受癌细胞提供新的潜在策略。在钠死亡方面,长期铂类药物暴露可导致离子稳态及能量代谢异常,并可能影响钠钾泵等离子转运系统[23],这些变化可能影响铂类药物摄取,并潜在改变耐药细胞对Na+超载相关死亡刺激的敏感性。因此,靶向钠钾泵诱导Na⁺超载介导的相关死亡,理论上可能与铂类引起的线粒体损伤形成协同抗肿瘤作用,但其具体机制仍有待进一步研究验证。

1.3 凋亡

细胞凋亡作为程序性细胞死亡的主要形式,主要由2条途径启动:内源性(线粒体介导)途径和外源性(死亡受体)途径[24],其调控失衡是卵巢癌铂类药物耐药的关键因素。卵巢癌细胞通过凋亡逃逸相关机制获得耐药性,凋亡通路的直接调控靶点包括Bcl-2家族蛋白和凋亡抑制因子(inhibitor of apoptotic protein,IAP)[25-26],间接调控通路则涉及DNA同源重组修复、微RNA调控和肿瘤蛋白p53(tumor protein p53,TP53)突变等生物学过程[27-28]。针对上述凋亡靶点的小分子药物与化疗药物联合使用已显示出良好效果,在逆转卵巢癌耐药中展现出潜力[29]。

1.4 自噬

自噬是细胞清除受损细胞器和蛋白质聚集体的一种机制,对维持细胞内环境稳定和细胞生存至关重要[6]。癌细胞中自噬的细胞保护作用被认为是一种潜在的化疗耐药机制[30]。顺铂可以通过激活泛素结合蛋白p62或高迁移率族蛋白B1(high mobility group box 1 protein,HMGB1)诱导卵巢癌细胞自噬,对卵巢癌顺铂耐药的发生起促进作用[31]。多条信号通路可通过上调自噬活性增强癌细胞对顺铂的耐药性,包括细胞外信号调节激酶(extracellular signal-regulated kinase,ERK)/哺乳动物雷帕霉素靶蛋白(mammalian target of rapamycin,mTOR)、PDZ连接激酶/己糖激酶2(PDZ-binding kinase/hexokinase 2,PBK/HK2)-ERK[32]。正常生理水平的自噬对维持细胞功能至关重要。抑癌基因PTEN、自噬效应蛋白Beclin-1的表达水平下调会抑制自噬活性,可能削弱化疗诱导的细胞死亡,反而促进耐药发展[33]。上述结果表明,自噬活性的动态平衡是化疗药物发挥抗肿瘤效应的必要前提,自噬过度激活或不足均可能介导卵巢癌顺铂耐药的发生。

1.5 坏死性凋亡

坏死性凋亡是一种依赖RIPK1/RIPK3/MLKL的类似坏死的细胞死亡形式[34],常在凋亡通路受抑制时被激活,可作为凋亡缺陷后癌细胞发生死亡的替代性途径。一方面,耐药卵巢癌细胞可通过下调坏死性凋亡关键蛋白RIPK3或上调IAP家族成员,逃避该死亡途径[35]。另一方面,坏死性凋亡的过度激活会释放损伤相关分子模式(damage-associated molecular patterns,DAMPs),诱发慢性炎症微环境,间接支持肿瘤生长与免疫逃逸[36]。

1.6 焦亡

焦亡是一种GSDM家族蛋白介导的程序性细胞死亡,其典型特征为细胞膜穿孔及促炎性细胞因子IL-1β的释放[37],主要通过caspase-1依赖的经典途径或caspase-4/5/11依赖的非经典途径激活[38]。在卵巢癌铂类耐药中,焦亡扮演双重角色:一方面,耐药细胞可通过下调GSDMD或抑制炎症小体NOD样受体热蛋白结构域相关蛋白3(NOD-like receptor family pyrin domain containing 3,NLRP3)的激活来逃避焦亡[39]。另一方面,化疗药物会诱导焦亡释放大量炎症介质,虽然可以杀伤部分癌细胞,但持续存在的炎性微环境也可能促进肿瘤增殖、侵袭和免疫抑制,间接加速耐药演变[40]。

1.7 铁死亡

铁死亡是一种铁依赖性程序性细胞死亡形式,其特征为铁过载、活性氧积累及脂质过氧化[9]。耐药癌细胞常通过上调SLC7A11与GPX4表达、激活核因子-E2相关因子2(nuclear factor erythroid 2-related factor 2,Nrf2)通路、上调硬脂酰辅酶A去饱和酶1(stearoyl-coenzyme A desaturase 1,SCD1)表达、增强System Xc-功能和调节脂质代谢,从而抵抗氧化损伤与铁死亡[41-43]。因此,通过使用GPX4抑制剂、System Xc-抑制剂或干预相关代谢通路来诱导铁死亡,可有效逆转铂耐药,成为潜在的治疗新策略[44-45]。

1.8 铜死亡

铜死亡是一种铜依赖性程序性细胞死亡方式[10]。铜死亡在卵巢癌铂类耐药中的作用主要与铜转运体对铂类药物代谢的调节有关。铜离子与铂类药物化学性质相似,共享部分转运途径:摄入蛋白CTR1促进铂类药物进入细胞,其低表达导致铂类药物摄取减少[46-47];而外排蛋白ATP7A/B的高表达可通过隔离或外排铂类药物,阻止其到达DNA靶点,从而诱发耐药[48]。此外,铜死亡关键基因FDX1、DLD的表达异常与免疫微环境相关,可能影响治疗反应和预后[49-50]。因此,靶向铜转运体或铜死亡通路有望逆转铂耐药、提高化疗敏感性。

不同程序性细胞死亡方式在卵巢癌铂耐药中的关键治疗靶点及其干预策略见表1。

2 不同程序性细胞死亡方式的相互作用与卵巢癌铂耐药

2.1 自噬与焦亡的相互作用

在铂耐药卵巢癌中,自噬主要充当焦亡的上游抑制器。在分子机制层面,自噬主要通过2条途径抑制NLRP3炎症小体介导的焦亡:其一,自噬清除受损线粒体,减少线粒体来源的活性氧和线粒体脱氧核糖核酸(mitochondrial deoxyribonucleic acid,mtDNA)释放,从而抑制NLRP3炎症小体组装[51-52];其二,自噬通过p62介导的溶酶体降解途径直接清除NLRP3、凋亡相关斑点样蛋白(apoptosis-associated speck-like protein containing a CARD,ASC)等炎症小体组分,降低caspase-1活化及下游GSDMD切割,最终减弱焦亡[53-55]。在卵巢癌化疗过程中,顺铂等药物可在特定分子背景下激活caspase-3/GSDME或NLRP3/caspase-1/GSDMD通路,促使细胞死亡模式从无炎症凋亡转向炎性焦亡;然而,耐药细胞往往上调自噬,抑制这一转换过程,导致治疗抵抗[56]。值得注意的是,焦亡具有显著的免疫原性,其释放的IL-1β、IL-18及DAMPs可激活抗肿瘤免疫应答,为克服耐药提供双重机制。因此,靶向自噬和焦亡(自噬抑制剂联合化疗)的干预策略虽能增强肿瘤杀伤效力,但也需考虑伴随的炎症反应。未来研究应基于GSDMD/GSDME表达、NLRP3活化状态、微管相关蛋白轻链3-II(microtubule-associated protein 1 light chain 3-II,LC3-II)/p62比例及线粒体自噬指标对患者进行精准分层,并探索自噬调节剂、焦亡诱导剂与免疫检查点抑制剂的合理组合方案。

2.2 铁死亡与焦亡的相互作用

铁死亡与焦亡在卵巢癌铂耐药中呈现复杂的互作关系,通过多重分子机制共同调控癌细胞命运。铁死亡以铁依赖性脂质过氧化为特征,而焦亡则通过GSDM家族蛋白介导的膜孔形成引发炎症性死亡,二者在肿瘤微环境中相互影响。研究[57]表明,焦亡释放的IL-1β、IL-18及游离脂肪酸可重塑肿瘤微环境,促进免疫抑制性细胞浸润,间接增强癌细胞对铂类药物或者聚腺苷二磷酸核糖聚合酶(poly ADP-ribose polymerase,PARP)抑制剂的耐受性;网膜脂肪细胞的GSDMD依赖性焦亡释放的脂质还为癌细胞提供能量支持,进一步促进化疗抵抗[58]。在分子层面,2种死亡方式通过ROS、线粒体损伤与脂质代谢紧密联系:焦亡引起的细胞膜完整性破坏与钙离子波动可促进脂质过氧化,增加铁死亡易感性;反之,铁死亡产生的氧化脂质与ROS可激活炎症小体,上调caspase-1或促进caspase-3介导的GSDME裂解,形成正反馈环路[59]。在铂耐药卵巢癌中,靶向抑制GPX4不仅能诱导铁死亡,还能通过NLRP3炎症小体激活GSDMD介导的焦亡,所释放的IL-1β可进一步增强抗肿瘤免疫应答,协同克服耐药[60-61]。值得注意的是,TP53突变通过双重机制介导耐药:一方面通过上调SLC7A11表达抑制铁死亡,另一方面通过抑制GSDME转录阻断焦亡。而敲除SLC7A11可同时恢复铁死亡敏感性并激活caspase-3/GSDME依赖的焦亡,从而显著逆转耐药表型[62]。此外,铁死亡释放的HMGB1可通过Toll样受体4(Toll-like receptor 4,TLR4)信号通路激活NLRP3炎症小体和GSDMD,进一步放大焦亡效应[63]。焦亡与铁死亡可以形成以ROS/脂质过氧化/炎症小体为核心的正反馈放大环路。这些发现揭示了靶向铁死亡和焦亡协同网络的治疗潜力,为克服卵巢癌铂耐药提供了新策略。

2.3 自噬与铁死亡的相互作用

自噬与铁死亡在卵巢癌铂耐药中呈现复杂的双向调控关系。正常生理状态下自噬通过维持细胞稳态发挥保护作用,但特定条件下可通过增加游离铁、提供脂质过氧化底物或降解GPX4等途径促进铁死亡,因此铁死亡也被视为一种依赖溶酶体的自噬性细胞死亡过程[64-65]。在分子机制层面,核受体共激活因子4(nuclear receptor coactivator 4,NCOA4)介导的铁蛋白自噬可释放铁蛋白中的铁,增加细胞内可变铁池,激活芬顿反应并提高脂质过氧化水平,从而增强铁死亡易感性[66]。而热激蛋白90(heat-shock protein 90,HSP90)则通过激活自噬相关蛋白7(autophagy related 7,ATG7)促进自噬体形成,一方面加速脂滴分解提供多不饱和脂肪酸,另一方面降解GPX4,双重调控铁死亡过程[67]。在顺铂耐药卵巢癌中,自噬呈现出双重调控特性:保护性自噬可通过清除受损线粒体、维持GSH/抗氧化稳态,提高铁死亡阈值,促进耐药形成;而特定类型的自噬(如脂滴自噬)则通过重塑脂质代谢增加对铁死亡诱导剂的敏感性[68-69]。抑制保护性自噬或靶向NCOA4介导的铁蛋白自噬可增加药物诱导的ROS与脂质过氧化,增强顺铂或铁死亡诱导剂的细胞毒性;在体内模型中,自噬抑制剂与铁死亡诱导剂联用呈现显著协同抗肿瘤效应[70]。然而,临床转化面临药物毒性、作用选择性与肿瘤异质性等挑战。未来研究应基于患者来源模型,结合LC3-II/p62、NCOA4、GPX4等生物标志物进行精准分层,并评估对正常组织的安全性,以推进自噬-铁死亡联合疗法的临床应用。

2.4 铁死亡与铜死亡的相互作用

铁死亡与铜死亡同作为金属离子依赖性的新型细胞死亡方式,对GSH、TP53、线粒体代谢及氧化应激具有调控作业,其复杂的相互作用为逆转卵巢癌铂类耐药提供了全新视角。其中GSH代谢轴处于调控核心位置,可同时抑制铁死亡和铜死亡。铂耐药细胞常伴有GSH水平异常升高,GSH既可以通过结合并外排铂类药物直接导致耐药,还可同时调控这2条死亡通路:GSH能维持GPX4活性,抑制脂质过氧化,从而保护细胞免于铁死亡[71];同时,它作为铜离子的强效螯合剂,缓冲了游离铜离子,提高铜死亡的阈值[72]。因此,靶向耗竭GSH(如抑制其合成关键转运体SLC7A11)可产生协同效应,既能诱发铁死亡,又能解除铜离子螯合以触发铜死亡。TP53的失活会影响这一平衡:TP53失活会解除对SLC7A11的抑制,导致GSH合成增加,增强细胞对铁死亡的抵抗性[73];同时,它驱动代谢向有氧糖酵解(瓦尔堡效应)重编程,抑制线粒体氧化磷酸化,可能在某种程度上降低细胞对铜死亡的敏感性[74]。通过联合靶向策略(共递送铁死亡与铜死亡诱导剂的纳米技术)[75],可同时扰动GSH缓冲系统、利用耐药细胞的代谢弱点,有望协同打破铂耐药细胞的防御平衡,为克服卵巢癌治疗瓶颈提供极具潜力的新方向。

2.5 铁死亡与双硫死亡的相互作用

铁死亡与双硫死亡作为2种新型的程序性细胞死亡形式,在卵巢癌及其铂类耐药中显示出潜在的拮抗与转换关系。在拮抗方面,SLC7A11作为细胞摄取胱氨酸、合成谷胱甘肽的关键转运体,在铂耐药卵巢癌细胞中常过度表达[76],是铁死亡与双硫死亡的共同调控节点:铁死亡依赖GSH维持抗脂质过氧化能力,而后双硫死亡则源于胱氨酸过量积累引发的二硫键应激。然而,在葡萄糖代谢受限的条件下,这种对立关系可被代谢重编程所打破。SLC7A11通过促进胱氨酸摄取和GSH合成来抑制脂质过氧化,从而拮抗铁死亡;但在葡萄糖供应受限或NADPH生成受阻的情况下,过量胱氨酸无法被有效还原,导致二硫键应激积累并触发双硫死亡[77]。因此,SLC7A11的功能并非单向保护,而是依赖于细胞代谢状态的动态调控开关,这表明SLC7A11在这2种死亡模式之间具有“双刃剑”效应。二者也存在转换或协同激活的潜力:当抑制葡萄糖代谢极大耗竭NADPH供应时,SLC7A11介导的胱氨酸摄入不仅激活双硫死亡,还会因抗氧化防御体系崩溃,削弱对脂质过氧化的防御,使细胞对铁死亡更加敏感[78]。具体而言,SLC7A11介导的胱氨酸向半胱氨酸的还原过程高度依赖NADPH供给。在卵巢癌微环境中,当葡萄糖摄取受抑制或者糖酵解/磷酸戊糖途径受阻时,细胞内NADPH水平显著下降,会引发2方面后果:一方面,胱氨酸无法被有效还原而在细胞内积累,诱导二硫键应激并触发双硫死亡;另一方面,NADPH耗竭同时削弱GSH再生能力并抑制GPX4活性,导致脂质过氧化失控,从而增强铁死亡敏感性。例如,在系统性葡萄糖缺乏的模型中,NADPH水平下降会阻断SLC7A11的正常胱氨酸还原途径,从而同时诱导双硫死亡和铁死亡[79]。因此,在葡萄糖限制/NADPH耗竭这一特定代谢背景下,双硫死亡与铁死亡并非简单的相互转换关系,而是通过共同依赖的SLC7A11/GSH/GPX4抗氧化轴发生协同诱导。该机制提示,通过代谢干预可在同一体系内同步激活2种细胞死亡途径,从而突破单一死亡模式的耐受性。

2.6 铁死亡与钠死亡的相互作用

钠死亡与铁死亡虽分别由Na⁺过载与铁依赖性脂质过氧化驱动,但在能量代谢、氧化应激及线粒体功能等关键层面存在显著交叉,并在卵巢癌铂耐药中形成潜在协同网络。一方面,NECSO的发生依赖腺苷三磷酸(adenosine triphosphate,ATP)耗竭导致钠钾泵功能失活,引起Na⁺内流失控和细胞渗透压破坏,而ATP水平下降同样会削弱GSH合成及GPX4活性,从而促进铁死亡发生,因此ATP耗竭是2种死亡方式的重要共同上游枢纽[80]。与此同时,NECSO诱导的Na⁺过载可破坏线粒体膜电位并促进ROS生成[81],而ROS积累又是驱动铁死亡脂质过氧化的核心因素,二者由此形成NECSO/ROS/铁死亡的正反馈放大回路。在线粒体层面,钠稳态失衡可进一步引发线粒体功能障碍、GSH耗竭及代谢紊乱,这些变化均为铁死亡提供了有利条件[82],提示NECSO可能作为铁死亡的前驱状态。此外,在“金属死亡”理论框架下,Na⁺与Fe²⁺等离子介导的细胞死亡被视为相互关联的网络系统,Na⁺失衡可能通过影响膜电位及铁代谢过程(铁摄取与储存)间接调控细胞对铁死亡的敏感性[83]。在卵巢癌铂耐药背景中,铁死亡已被证实可通过抑制GPX4、耗竭GSH及提高游离铁水平来恢复顺铂敏感性[84];目前尚缺乏NECSO参与卵巢癌铂耐药的直接研究证据,但铂类药物诱导的线粒体损伤与ATP下降可能同步激活NECSO与铁死亡,从而增强细胞死亡效应。耐药细胞通常具有增强的抗氧化能力和更稳定的离子稳态,因此诱导NECSO有望通过破坏离子平衡削弱其适应能力,协同促进铁死亡。总体而言,NECSO与铁死亡在铂耐药中更可能表现为协同促进关系,通过能量耗竭、ROS积累及线粒体损伤形成多层级放大网络,为克服卵巢癌化疗耐药提供新的理论依据与潜在干预靶点。

2.7 泛凋亡

泛凋亡并非独立的细胞死亡类型,而是由泛凋亡小体(PANoptosome)多蛋白复合物调控的整合性死亡过程,可同时激活凋亡、焦亡和坏死性凋亡3种程序性死亡通路[85]。其核心特征在于多通路协同激活:泛凋亡小体可同时募集caspase-8(凋亡)、caspase-1(焦亡)及RIPK3(坏死性凋亡)等关键执行分子,形成死亡信号交叉点[86];当单一通路被抑制时,其他通路可代偿性激活,使细胞难以通过单一机制逃避死亡,这一特性对克服卵巢癌铂耐药具有重要意义。生物信息学研究[87]构建的泛凋亡相关基因(PANoptosis-related gene,PRG)预后模型显示,黑色素瘤缺乏因子2(absent in melanoma 2,AIM2)、ASC、Z-DNA结合蛋白1(Z-DNA binding protein 1,ZBP1)等核心基因构成的风险评分与卵巢癌患者生存期、肿瘤免疫浸润特征及药物敏感性显著相关。在免疫调控层面,泛凋亡通过释放DAMPs(HMGB1、ATP)和促炎性细胞因子(IL-1β、IL-18)激活抗原呈递细胞,增强CD8⁺ T细胞浸润;而泛凋亡高风险亚型患者肿瘤组织中M2型巨噬细胞和癌症相关成纤维细胞比例增高,提示泛凋亡状态与免疫微环境存在动态平衡[88]。

在耐药逆转策略方面,由于泛凋亡依赖多节点协同激活,理想的诱导剂需要同时作用于caspase-8、RIPK3及炎症小体等核心调控节点。当前探索的方向主要包括2类:1)利用DNA损伤剂或表观遗传调控药物激活干扰素信号以上调ZBP1表达,从而促进泛凋亡小体组装[89];2)铂类药物如奥沙利铂则可通过累积DNA损伤并激活环鸟苷酸-腺苷酸合成酶/干扰素基因刺激因子(cyclic GMP-AMP synthase/stimulator of interferon genes,cGAS-STING)通路为泛凋亡激活提供上游信号[90]。此外,第2个线粒体衍生半胱天冬氨酸蛋白酶激活剂模拟物LCL161、二硫仑/铜离子复合物等多靶点药物,能够同时激活凋亡、焦亡和坏死性凋亡,已在多种肿瘤模型中显示出逆转耐药的作用[91]。近年研究[92]还发现,PARP抑制剂除了引起DNA损伤累积,还可增强ROS水平和炎症信号,与泛凋亡诱导策略联用可能具有协同效应,尤其是在同源重组缺陷(homologous recombination deficiency,HRD)背景下,持续的DNA损伤有望进一步促进ZBP1、NLRP3和RIPK3相关死亡网络的激活[93]。

然而,泛凋亡的广谱激活亦可能引发正常组织的炎症性损伤,因此其临床转化关键在于提高肿瘤特异性。当前策略包括:利用肿瘤特异性分子ZBP1/AIM2为触发节点,结合肿瘤微环境的高ROS或代谢重编程特征,实现条件性激活,或通过纳米递送或抗体偶联药物实现靶向释放。综上,泛凋亡通过多通路协同激活打破单一死亡路径依赖,其治疗价值不仅在于增强细胞杀伤,更在于绕过耐药机制。未来应从强效诱导转向选择性激活,并结合联合治疗与精准递送策略,以实现对铂耐药卵巢癌的高效且安全的干预。

上述各类程序性细胞死亡方式通过共享分子节点和信号通路形成复杂的调控网络,其相互作用模式及潜在治疗策略总结见表2。

3 结 语

铂耐药是制约卵巢癌疗效的核心难题,其背后并非单一死亡通路的功能失调,而是多种程序性细胞死亡构成的复杂网络发生适应性改变。本综述结合近年来在程序性细胞死亡领域的新进展,从多维度、跨通路的角度,系统阐述了双硫死亡、钠死亡、凋亡、坏死性凋亡、自噬、焦亡、铁死亡及铜死亡等多种细胞死亡方式在卵巢癌治疗中独特的作用机制,通过精准调控相关信号通路,可为患者提供更加个性化和高效的治疗方案。以程序性细胞死亡激活为核心的促死亡耐药逆转策略虽具有良好的应用前景,但临床转化高度依赖患者精准分层与安全性控制。

不同类型的程序性死亡对肿瘤分子背景有明显依赖性。例如,SLC7A11和GPX4高表达说明肿瘤的抗氧化能力较强,此类肿瘤通常对铁死亡诱导剂敏感性较低;与之相对的是,SLC7A11高表达的细胞在葡萄糖缺乏时反而容易发生双硫死亡,可作为联合干预的一个切入点。焦亡的激活受GSDMD/GSDME表达水平影响,而ZBP1、AIM2、caspase-8等分子则与泛凋亡的激活相关。联合治疗方面,铂类药物奥沙利铂能通过诱发DNA损伤并激活cGAS-STING通路,提高肿瘤对泛凋亡的易感性;对于SLC7A11高表达的肿瘤,代谢干预(限制葡萄糖或抑制戊糖磷酸途径)有望同时触发双硫死亡,干预时需兼顾此类肿瘤本身的铁死亡抵抗特性。

需要强调的是,TP53、caspase家族、GSDM蛋白、GPX4等关键分子把氧化还原状态、线粒体功能、金属离子代谢和能量重编程串联在一起。例如,铁死亡与铜死亡在离子稳态上相互影响,铁死亡与双硫死亡在抗氧化系统中存在竞争,焦亡等炎性死亡模式与免疫微环境之间形成反馈,泛凋亡则体现出通路间的代偿能力。这也解释了为什么单靶点干预往往效果有限。未来研究应转向生物标志物指导下的多通路协同诱导策略。

此外,非选择性激活程序性死亡也可能伤及正常组织,尤其是肝、肾等对氧化应激和炎症损伤较为敏感的高代谢器官。靶向递送系统(纳米载体、脂质体、抗体偶联药物)可借助肿瘤特异性分子或微环境特征实现选择性释放,能提高瘤内药物浓度并降低全身毒性。此外,化疗引起的离子稳态失衡也值得关注:顺铂会干扰线粒体ATP合成,而维持钠稳态的钠钾泵高度依赖ATP,这意味着Na⁺稳态失调可能间接参与铂耐药适应过程,但目前尚缺乏确凿证据,也并非一种独立的程序性死亡方式。

综上,未来卵巢癌促死亡治疗的发展方向,不应仅局限于开发更高活性的死亡诱导剂,更在于构建生物标志物分层、多通路联合诱导、精准递送的一体化体系,以实现对铂耐药卵巢癌的高效、低毒干预。

参考文献

[1]

Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA A Cancer J Clin, 2021, 71(3): 209-249.

[2]

Yang L, Xie HJ, Li YY, et al. Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)[J]. Oncol Rep, 2022, 47(4): 82.

[3]

Pokhriyal R, Hariprasad R, Kumar L, et al. Chemotherapy resistance in advanced ovarian cancer patients[J]. Biomark Cancer, 2019, 11: 1179299X19860815.

[4]

Yimit A, Adebali O, Sancar A, et al. Differential damage and repair of DNA-adducts induced by anti-cancer drug cisplatin across mouse organs[J]. Nat Commun, 2019, 10: 309.

[5]

Mantri S, Doshi GM. Reactivating apoptotic pathways in cancer: a review of novel therapeutic approaches[J]. Eur J Pharmacol, 2025, 1003: 177965.

[6]

Jung S, Jeong H, Yu SW. Autophagy as a decisive process for cell death[J]. Exp Mol Med, 2020, 52(6): 921-930.

[7]

Roberts JZ, Crawford N, Longley DB. The role of ubiquitination in apoptosis and necroptosis[J]. Cell Death Differ, 2022, 29(2): 272-284.

[8]

Resta SC, Guerra F, Talà A, et al. Beyond inflammation: role of pyroptosis pathway activation by gram-negative bacteria and their outer membrane vesicles (OMVs) in the interaction with the host cell[J]. Cells, 2024, 13(21): 1758.

[9]

Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease[J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282.

[10]

Wang Y, Chen Y, Zhang J, et al. Cuproptosis: a novel therapeutic target for overcoming cancer drug resistance[J]. Drug Resist Updat, 2024, 72: 101018.

[11]

赵琪琪, 杜雪芹, 刘松华, 等. SLC7A11表达与双硫死亡、铁死亡及肿瘤关系的研究进展[J]. 江苏大学学报(医学版), 2023, 33(5): 398-403.

[12]

ZHAO Qiqi, DU Xueqin, LIU Songhua, et al. Research progress on the relationship between SLC7A11 expression and disulfide death, iron death and tumor[J]. Journal of Jiangsu University. Medicine Edition, 2023, 33(5): 398-403.

[13]

Fu W, Wang J, Li T, et al. Persistent activation of TRPM4 triggers necrotic cell death characterized by sodium overload[J]. Nat Chem Biol, 2025, 21(8): 1238-1249.

[14]

Sazonova E, Yapryntseva M, Pervushin N, et al. Cancer drug resistance: targeting proliferation or programmed cell death[J]. Cells, 2024, 13(5): 388.

[15]

Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J]. Nat Cell Biol, 2023, 25(3): 404-414.

[16]

Zheng P, Zhou C, Ding Y, et al. Disulfidptosis: a new target for metabolic cancer therapy[J]. J Exp Clin Cancer Res, 2023, 42(1): 103.

[17]

Cong Y, Cai G, Ding C, et al. Disulfidptosis-related signature elucidates the prognostic, immunologic, and therapeutic characteristics in ovarian cancer[J]. Front Genet, 2024, 15: 1378907.

[18]

Fantone S, Piani F, Olivieri F, et al. Role of SLC7A11/xCT in ovarian cancer[J]. Int J Mol Sci, 2024, 25(1): 587.

[19]

Chang W, Gao W, Luo B, et al. Comprehensive insights into the role of TRPM4 in pan-cancer progression and immune regulation[J]. ImmunoTargets Ther, 2025, 14: 831-848.

[20]

Dai Y, Wang H, Wang W, et al. Multidimensional pan cancer analysis of the sodium induced cell death gene TRPM4 [J]. Sci Rep, 2025, 15: 29768.

[21]

Guo J, Liu F, Yang X, et al. TRPM4 channels contribute to Adriamycin chemoresistance in breast cancer cells[J]. Eur J Pharmacol, 2025, 998: 177637.

[22]

Wang J, Chen J, Fan K, et al. Inhibition of endoplasmic reticulum stress cooperates with SLC7A11 to promote disulfidptosis and suppress tumor growth upon glucose limitation[J]. Adv Sci, 2025, 12(7): 2408789.

[23]

Atallah GA, Kampan NC, Chew KT, et al. Predicting prognosis and platinum resistance in ovarian cancer: role of immunohistochemistry biomarkers[J]. Int J Mol Sci, 2023, 24(3): 1973.

[24]

Oronsky B, Caroen S, Oronsky A, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management[J]. Cancer Chemother Pharmacol, 2017, 80(5): 895-907.

[25]

Vitale I, Pietrocola F, Guilbaud E, et al. Apoptotic cell death in disease-Current understanding of the NCCD 2023[J]. Cell Death Differ, 2023, 30(5): 1097-1154.

[26]

Zarei MA, Nikzad H, Shabani Z, et al. Dendrosomal Curcumin Nanoformulation induces apoptosis via Bax/Bcl-2 in human ovarian cancer OVCAR3 cells[J]. Cancer Treat Res Commun, 2025, 44: 100981.

[27]

Ye Q, Zhuang XZ, Li J, et al. Targeting the inhibitors of apoptosis proteins (IAPs) to combat drug resistance in cancers[J]. Front Pharmacol, 2025, 16: 1562167.

[28]

Alatise KL, Gardner S, Alexander-Bryant A. Mechanisms of drug resistance in ovarian cancer and associated gene targets[J]. Cancers, 2022, 14(24): 6246.

[29]

Nayak R, Pandey S, Kumar D, et al. Signaling networks and MiRNA crosstalk in ovarian cancer chemoresistance[J]. J Ovarian Res, 2025, 18(1): 185.

[30]

Del Bufalo D, Damia G. Overview of BH3 mimetics in ovarian cancer[J]. Cancer Treat Rev, 2024, 129: 102771.

[31]

Tonkin-Reeves A, Giuliani CM, Price JT. Inhibition of autophagy; an opportunity for the treatment of cancer resistance[J]. Front Cell Dev Biol, 2023, 11: 1177440.

[32]

Yan X, Qu X, Xu L, et al. Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer[J]. Cancer Cell Int, 2020, 20(1): 128.

[33]

Ma H, Li Y, Wang X, et al. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma[J]. Cell Death Dis, 2019, 10(3): 166.

[34]

Nowak M, Klink M. The role of tumor-associated macrophages in the progression and chemoresistance of ovarian cancer[J]. Cells, 2020, 9(5): 1299.

[35]

Horne C, Samson A, Murphy J. The web of death: the expanding complexity of necroptotic signaling[J]. Trends Cell Biol, 2023, 33(2): 162-174.

[36]

Shi SN, Xu Q, Jiao X, et al. ATR-mediated phosphorylation of RIPK1 inhibits DNA damage-induced necroptosis[J]. Biochem Pharmacol, 2025, 240: 117069.

[37]

Li L, Tong A, Zhang Q, et al. The molecular mechanisms of MLKL-dependent and MLKL-independent necrosis[J]. J Mol Cell Biol, 2021, 13(1): 3-14.

[38]

Liu Z, Wang C, Lin C. Pyroptosis as a double-edged sword: The pathogenic and therapeutic roles in inflammatory diseases and cancers[J]. Life Sci, 2023, 318: 121498.

[39]

Berkel C, Keskin A, Cacan E. Chemo-sensitive and chemo-resistant ovarian cancer cells show differences in cellular processes leading to pyroptotic cell death[J]. Pathol Res Pract, 2025, 269: 155911.

[40]

Ershaid N, Sharon Y, Doron H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun, 2019, 10: 4375.

[41]

Li W, Zhao X, Zhang R, et al. Silencing of NLRP3 sensitizes chemoresistant ovarian cancer cells to cisplatin[J]. Mediat Inflamm, 2023, 2023: 7700673.

[42]

Wu X, Shen S, Qin J, et al. High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer[J]. BJOG, 2022, 129(S2): 40-49.

[43]

Zhao H, Xu Y, Shang H. Ferroptosis: a new promising target for ovarian cancer therapy[J]. Int J Med Sci, 2022, 19(13): 1847-1855.

[44]

Wang N, Chen M, Wu M, et al. High-adhesion ovarian cancer cell resistance to ferroptosis: The activation of NRF2/FSP1 pathway by junctional adhesion molecule JAM3[J]. Free Radic Biol Med, 2025, 228: 1-13.

[45]

Kapper C, Oppelt P, Arbeithuber B, et al. Targeting ferroptosis in ovarian cancer: Novel strategies to overcome chemotherapy resistance[J]. Life Sci, 2024, 349: 122720.

[46]

Cheng Q, Bao L, Li M, et al. Erastin synergizes with cisplatin via ferroptosis to inhibit ovarian cancer growth in vitro and in vivo[J]. J Obstet Gynaecol Res, 2021, 47(7): 2481-2491.

[47]

Sun S, Cai J, Yang Q, et al. The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: a meta-analysis of literatures and datasets[J]. Oncotarget, 2017, 8(9): 16036-16051.

[48]

Wang X, Lou Q, Fan T, et al. Copper transporter Ctr1 contributes to enhancement of the sensitivity of cisplatin in esophageal squamous cell carcinoma[J]. Transl Oncol, 2023, 29: 101626.

[49]

Ge EJ, Bush AI, Casini A, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia[J]. Nat Rev Cancer, 2022, 22(2): 102-113.

[50]

Zou Q, Chen Y, Liu D, et al. Cuproptosis inhibits tumor progression and enhances cisplatin toxicity in ovarian cancer[J/OL]. FASEB J, 2025, 39(6): e70484[2026-02-15].

[51]

Wang K, Zhang Y, Ao M, et al.Multi-omics analysis defines a cuproptosis-related prognostic model for ovarian cancer: Implication of WASF2 in cuproptosis resistance[J]. Life Sci, 2023,332:122081.

[52]

Gupta S, Cassel S, Sutterwala F, et al. Regulation of the NLRP3 inflammasome by autophagy and mitophagy[J/OL]. Immunol Rev, 2025, 329(1): e13410[2026-02-15].

[53]

Luo T, Jia X, Feng W, et al. Bergapten inhibits NLRP3 inflammasome activation and pyroptosis via promoting mitophagy[J]. Acta Pharmacol Sin, 2023, 44(9): 1867-1878.

[54]

Zhang D, Zhang Y, Pan J, et al. Degradation of NLRP3 by p62-dependent-autophagy improves cognitive function in Alzheimer’s disease by maintaining the phagocytic function of microglia[J]. CNS Neurosci Ther, 2023, 29(10): 2826-2842.

[55]

Hos NJ, Fischer J, Murthy AMV, et al. P62 inhibits IL-1β release during Salmonella Typhimurium infection of macrophages[J]. Front Cell Infect Microbiol, 2025, 15: 1495567.

[56]

Biasizzo M, Kopitar-Jerala N. Interplay between NLRP3 inflammasome and autophagy[J]. Front Immunol, 2020, 11: 591803.

[57]

Wang X, Yin Y, Qian W, et al. Citric acid of ovarian cancer metabolite induces pyroptosis via the caspase-4/TXNIP-NLRP3-GSDMD pathway in ovarian cancer[J/OL]. FASEB J, 2022, 36(6): e22362[2026-02-15].

[58]

Chen D, Guo S, Tang X, et al. Combination of ruthenium (II) polypyridyl complex Δ-Ru1 and Taxol enhances the anti-cancer effect on Taxol-resistant cancer cells through Caspase-1/GSDMD- mediated pyroptosis[J]. J Inorg Biochem, 2022, 230: 111749.

[59]

Lin C, Liang Y, Tsai HF, et al. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer[J]. J Biomed Sci, 2024, 31(1): 62.

[60]

Rao Z, Zhu Y, Yang P, et al. Pyroptosis in inflammatory diseases and cancer[J]. Theranostics, 2022, 12(9): 4310-4329.

[61]

Li Y, Gong X, Hu T, et al. Two novel prognostic models for ovarian cancer respectively based on ferroptosis and necroptosis[J]. BMC Cancer, 2022, 22(1): 74.

[62]

Feng Q, Hao S, Fang P, et al. Role of GPX4 inhibition-mediated ferroptosis in the chemoresistance of ovarian cancer to Taxol in vitro[J]. Mol Biol Rep, 2023, 50(12): 10189-10198.

[63]

Wang Y, Yi Y. CISD2 downregulation participates in the ferroptosis process of human ovarian SKOV-3 cells through modulating the wild type p53-mediated GLS2/SAT1/SLC7A11 and Gpx4/TRF signaling pathway[J]. Tissue Cell, 2024, 89: 102458.

[64]

Xie SS, Deng Y, Guo SL, et al. Endothelial cell ferroptosis mediates monocrotaline-induced pulmonary hypertension in rats by modulating NLRP3 inflammasome activation[J]. Sci Rep, 2022, 12: 3056.

[65]

Xue Q, Yan D, Chen X, et al. Copper-dependent autophagic degradation of GPX4 drives ferroptosis[J]. Autophagy, 2023, 19(7): 1982-1996.

[66]

Zhang H, Gao Y, Wang C, et al. NCOA4-mediated ferritinophagy aggravate intestinal oxidative stress and ferroptosis after traumatic brain injury[J]. Biochem Biophys Res Commun, 2023, 688: 149065.

[67]

Gryzik M, Asperti M, Denardo A, et al. NCOA4-mediated ferritinophagy promotes ferroptosis induced by erastin, but not by RSL3 in HeLa cells[J]. Biochim Biophys Acta Mol Cell Res, 2021, 1868(2): 118913.

[68]

Wang H, Luo X, Yang B, et al. XPR1 promotes ovarian cancer growth and regulates MHC-I through autophagy[J]. Genes Dis, 2025, 12(5): 101507.

[69]

Kirkwood-Donelson KI, Jarmusch AK, Bortner CD, et al. Metabolic consequences of erastin-induced ferroptosis in human ovarian cancer cells: an untargeted metabolomics study[J]. Front Mol Biosci, 2025, 11: 1520876.

[70]

Al-Mutairi AA, Alkhatib MH. Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells[J]. J Microencapsul, 2022, 39(5): 467-480.

[71]

Liu H, Shen L, et al. Mechanistic insights into the iron-sulfur cluster-dependent interaction of the autophagy receptor NCOA4 with the E3 ligase HERC2[J/OL]. Proc Natl Acad Sci U S A, 2025, 122(30): e2510269122[2026-02-15].

[72]

Shan X, Chen C, Zou D, et al. Suppression of ferroptosis through the SLC7A11/glutathione/glutathione peroxidase 4 axis contributes to the therapeutic action of the Tangshenning formula on diabetic renal tubular injury[J]. Chin Med, 2024, 19(1): 151.

[73]

Liu J, Tang H, Chen F, et al. NFE2L2 and SLC25A39 drive cuproptosis resistance through GSH metabolism[J]. Sci Rep, 2024, 14: 29579.

[74]

Liao T, Xu X, Wang G, et al. p53-mediated suppression of the SLC7 A11/GPX4 signaling pathway promotes trophoblast ferroptosis in preeclampsia[J]. BMC Biol, 2025, 23(1): 141.

[75]

Xiong C, Ling H, Hao Q, et al. Cuproptosis: p53-regulated metabolic cell death?[J]. Cell Death Differ, 2023, 30(4): 876-884.

[76]

Abu-Serie MM, Barakat A, Ramadan S, et al. Superior cuproptotic efficacy of diethyldithiocarbamate-Cu4O3 nanoparticles over diethyldithiocarbamate-Cu2O nanoparticles in metastatic hepatocellular carcinoma[J]. Front Pharmacol, 2024, 15: 1388038.

[77]

Yang R, Wang Y, Wei Z, et al. The role of molecular subtypes and immune infiltration characteristics based on disulfidptosis-related genes in ovarian cancer[J]. Discov Oncol, 2024, 15(1): 596.

[78]

Qiu H, Liu J, Shao N, et al. SLC7A11 as a bridge between ferroptosis and disulfidptosis: a promising target for tumor treatment[J]. Cell Commun Signal, 2025, 23(1): 460.

[79]

Li Q, University S, Wu Z, et al. Enhancing ferroptosis-mediated radiosensitization via synergistic disulfidptosis induction[J]. ACS Nano, 2025, 19(1): 1757-1770.

[80]

Zhang M, Zheng H, Zhu X, et al. Synchronously evoking disulfidptosis and ferroptosis via systematical glucose deprivation targeting SLC7A11/GSH/GPX4 antioxidant axis[J]. ACS Nano, 2025, 19(14): 14233-14248.

[81]

Wang J, Tian Q, Liu Y, et al. Targeting metalloptosis in tumor therapy: from molecular mechanisms to application of metal nanoparticles[J]. Mol Cancer, 2025, 24(1): 260.

[82]

Heiserman JP, Minhas Z, Nikpayam E, et al. Targeting heat shock protein 27 and fatty acid oxidation augments cisplatin treatment in cisplatin-resistant ovarian cancer cell lines[J]. Int J Mol Sci, 2023, 24(16): 12638.

[83]

Liu D, Hu Z, Lu J, et al. Redox-regulated iron metabolism and ferroptosis in ovarian cancer: molecular insights and therapeutic opportunities[J]. Antioxidants, 2024, 13(7): 791.

[84]

Subburayan K, Thayyullathil F, Pallichankandy S, et al. Superoxide-mediated ferroptosis in human cancer cells induced by sodium selenite[J]. Transl Oncol, 2020, 13(11): 100843.

[85]

Guo K, Lu M, Bi J, et al. Ferroptosis: mechanism, immunotherapy and role in ovarian cancer[J]. Front Immunol, 2024, 15: 1410018.

[86]

Pandian N, Kanneganti TD. PANoptosis: a unique innate immune inflammatory cell death modality[J]. J Immunol, 2022, 209(9): 1625-1633.

[87]

Sun X, Yang Y, Meng X, et al. PANoptosis: Mechanisms, biology, and role in disease[J]. Immunol Rev, 2024, 321(1): 246-262.

[88]

Liu Y, Lyu G. Construction of a PANoptosis-related prognostic signature for predicting prognosis, tumor microenvironment, and immune response in ovarian cancer[J]. Curr Med Chem, 2025, 32(35): 7840-7858.

[89]

Cao L, Zhang S, Peng H, et al. Identification and validation of anoikis-related lncRNAs for prognostic significance and immune microenvironment characterization in ovarian cancer[J]. Aging, 2024, 16(2): 1463-1483.

[90]

Wang F, Li K, Wang W, et al. Sensing of endogenous retroviruses-derived RNA by ZBP1 triggers PANoptosis in DNA damage and contributes to toxic side effects of chemotherapy[J]. Cell Death Dis, 2024, 15(10): 779.

[91]

Song Q, Fan Y, Zhang H, et al. Z-DNA binding protein 1 orchestrates innate immunity and inflammatory cell death[J]. Cytokine Growth Factor Rev, 2024, 77: 15-29.

[92]

Prasopporn S, Suppramote O, Ponvilawan B, et al. Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma[J]. Front Oncol, 2023, 12: 1124912.

[93]

Lau C, Seow K, Chen K. The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review[J]. Int J Mol Sci, 2022, 23(15): 8125.

[94]

Subbarao Malireddi R, Sharma B, Bynigeri R, et al. ZBP1 drives IAV-induced NLRP3 inflammasome activation and lytic cell death, PANoptosis, independent of the necroptosis executioner MLKL[J]. Viruses, 2023, 15(11): 2141.

基金资助

RIGHTS & PERMISSIONS

开放获取(Open access):本文遵循知识共享许可协议,允许第三方用户按照署名-非商业性使用-禁止演绎4.0(CC BY-NC-ND 4.0)的方式,在任何媒介以任何形式复制、传播本作品(https://creativecommons.org/licenses/by-nc-nd/4.0/)。

AI Summary AI Mindmap
PDF (658KB)

258

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉